Last update 21 Nov 2024
Denosumab biosimilar (Alkem Laboratories)
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms |
Target |
Mechanism RANKL inhibitors(Tumor necrosis factor ligand superfamily member 11 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Gene Sequence
Sequence Code 143522H
The sequence is quoted from: *****
Sequence Code 94568L
The sequence is quoted from: *****
Related
3
Clinical Trials associated with Denosumab biosimilar (Alkem Laboratories)A Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Enzene Denosumab (ENZ215) and Prolia® in Postmenopausal Women With Osteoporosis
A Randomized, Double-blind, Three-arm, Parallel-group, Single-dose Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Denosumab (ENZ215, EU-sourced Prolia®, and US-sourced Prolia®) in Healthy Adult Male Volunteers
A Prospective, Active-controlled, Randomized, Double blind, Multicenter, Phase III Study to Compare the Safety and Efficacy of Biosimilar Denosumab of Enzene Biosciences Limited versus Innovator Denosumab in the Treatment of Postmenopausal Osteoporosis
100 Clinical Results associated with Denosumab biosimilar (Alkem Laboratories)
Login to view more data
100 Translational Medicine associated with Denosumab biosimilar (Alkem Laboratories)
Login to view more data
100 Patents (Medical) associated with Denosumab biosimilar (Alkem Laboratories)
Login to view more data
100 Deals associated with Denosumab biosimilar (Alkem Laboratories)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Osteoporosis, Postmenopausal | Phase 3 | CZ | 04 Jul 2022 | |
| Osteoporosis, Postmenopausal | Phase 3 | CZ | 04 Jul 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free